Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : JPMorgan Adjusts Thermo Fisher Scientific PT to $700 From $600, Maintains Overweight Rating

09/20/2021 | 09:41am EDT


© MT Newswires 2021
All news about THERMO FISHER SCIENTIFIC
04:20pTHERMO FISHER SCIENTIFIC INC. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
08:35aThermo Fisher System Authorized for Covid-19 Saliva Testing
DJ
10/15THERMO FISHER SCIENTIFIC : UK Competition Regulator to Launch Inquiry Into Thermo Fisher's..
MT
10/15UK Watchdog to Investigate Thermo Fisher's Planned Acquisition of PPD
DJ
10/11THERMO FISHER SCIENTIFIC : to Hold Earnings Conference Call on Wednesday, October 27, 2021
PR
10/07Q LINEA : ASTar launched in Europe
AQ
10/07Thermo Fisher Scientific Officially Launches ASTar for the European Market
CI
10/07Health Care Stocks Gain Premarket Thursday
MT
10/07THERMO FISHER SCIENTIFIC : Prices Notes Offering Totaling 5.25 Billion Euros
MT
10/07Thermo Fisher Scientific and Q-Linea Launch ASTar System, A Rapid Antimicrobial Suscept..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 36 041 M - -
Net income 2021 7 156 M - -
Net Debt 2021 18 490 M - -
P/E ratio 2021 32,6x
Yield 2021 0,17%
Capitalization 231 B 231 B -
EV / Sales 2021 6,93x
EV / Sales 2022 6,25x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 588,03 $
Average target price 642,29 $
Spread / Average Target 9,23%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors